

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

32. The polypeptide of claim 31, comprising all or part of the amino acid sequence of SEQ ID NO. 9 or SEQ ID NO. 16, or a derivative thereof.

33. The polypeptide of claim 31, comprising all or part of the amino acid sequence of SEQ ID NO. 31 or SEQ ID NO. 22, or a derivative thereof.

34. The polypeptide of claim 31, comprising all or part of the amino acid sequence of SEQ ID NO. 33, or a derivative thereof.

35. The polypeptide of claim 33, consisting of the amino acid sequence of SEQ ID NO. 22.

36. A nucleic acid encoding a polypeptide of claim 31.

37. A nucleic acid encoding a polypeptide of claim 32.

38. A nucleic acid encoding a polypeptide of claim 33.

39. A nucleic acid encoding a polypeptide of claim 34.

40. A nucleic acid encoding a polypeptide of claim 35.

41. The nucleic acid of claim 36, comprising all or part of the nucleotide sequence of SEQ ID No. 15 or SEQ ID No. 21, or a nucleotide sequence derivative thereof.

42. The nucleic acid of claim 36, comprising all or part of the nucleotide sequence of SEQ ID No. 32, or a nucleotide sequence derivative thereof.

43. The nucleic acid of claim 36, comprising the nucleotide sequence of SEQ ID NO. 15 or SEQ ID NO. 30.

44. The nucleic acid of claim 37, comprising the nucleotide sequence of SEQ ID NO. 15 or SEQ ID NO. 30.

45. The nucleic acid of claim 36, consisting of the nucleotide sequence of SEQ ID NO. 21.

46. The nucleic acid of claim 37, consisting of the nucleotide sequence of SEQ ID NO. 21.

47. The nucleic acid of claim 36, consisting of a nucleotide sequence selected from the group consisting of SEQ ID NO. 15, 21, 30 and 32.

48. A recombinant host cell comprising an introduced nucleic acid of claim 37.
49. A recombinant host cell comprising an introduced nucleic acid of claim 38.
50. A recombinant host cell comprising an introduced nucleic acid of claim 39.
51. A recombinant host cell comprising an introduced nucleic acid of claim 40.
52. A recombinant host cell comprising an introduced nucleic acid of claim 47.
53. A vector comprising a nucleic acid of claim 37.
54. A vector comprising a nucleic acid of claim 38.
55. A vector comprising a nucleic acid of claim 39.
56. A vector comprising a nucleic acid of claim 40.
57. A vector comprising a nucleic acid of claim 47.
58. The vector of claim 53 that is a plasmid vector, a cosmid or any DNA not encapsidated by a virus.
59. The vector of claim 54 that is a plasmid vector, a cosmid or any DNA not encapsidated by a virus.
60. The vector of claim 55 that is a plasmid vector, a cosmid or any DNA not encapsidated by a virus.
61. The vector of claim 56 that is a plasmid vector, a cosmid or any DNA not encapsidated by a virus.
62. The vector of claim 57 that is a plasmid vector, a cosmid or any DNA not encapsidated by a virus.
63. The vector of claim 53 that is a recombinant viral vector or replication-defective recombinant viral vector.
64. The vector of claim 54 that is a recombinant viral vector or replication-defective recombinant viral vector.
65. The vector of claim 55 that is a recombinant viral vector or replication-defective recombinant viral vector.

66. The vector of claim 56 that is a recombinant viral vector or replication-defective recombinant viral vector.

67. The vector of claim 57 that is a recombinant viral vector or replication-defective recombinant viral vector.

68. A method for preparing a polypeptide, comprising introducing into a host cell a nucleic acid encoding a polypeptide of claim 32 operably linked to expression control sequences, culturing the cell under conditions for expressing the polypeptide, and isolating the polypeptide from the cell.

69. A method for preparing a polypeptide, comprising introducing into a host cell a nucleic acid encoding a polypeptide of claim 33 operably linked to expression control sequences, culturing the cell under conditions for expressing the polypeptide, and isolating the polypeptide from the cell.

70. A method for preparing a polypeptide, comprising introducing into a host cell a nucleic acid encoding a polypeptide of claim 34 operably linked to expression control sequences, culturing the cell under conditions for expressing the polypeptide, and isolating the polypeptide from the cell.

71. A method for preparing a polypeptide, comprising introducing into a host cell a nucleic acid encoding a polypeptide of claim 35 operably linked to expression control sequences, culturing the cell under conditions for expressing the polypeptide, and isolating the polypeptide from the cell.

72. An antisense oligonucleotide having a sequence complementary to the nucleic acid of claim 41, the oligonucleotide capable of partially inhibiting the production of a polypeptide of claim 31.

73. An antisense oligonucleotide having a sequence complementary to the nucleic acid of claim 42, the oligonucleotide capable of partially inhibiting the production of a polypeptide of claim 31.

74. An antisense oligonucleotide having a sequence complementary to the nucleic acid of claim 43, the oligonucleotide capable of partially inhibiting the production of a polypeptide of claim 31.

75. An antisense oligonucleotide having a sequence complementary to the nucleic acid of claim 44, the oligonucleotide capable of partially inhibiting the production of a polypeptide of claim 31.

76. An antisense oligonucleotide having a sequence complementary to the nucleic acid of claim 47, the oligonucleotide capable of partially inhibiting the production of a polypeptide of claim 31.

77. A nucleic acid probe capable of hybridizing with a nucleic acid of claim 37, or mRNA corresponding to the nucleic acid of claim 37.

78. A nucleic acid probe capable of hybridizing with a nucleic acid of claim 38, or mRNA corresponding to the nucleic acid of claim 38.

79. A nucleic acid probe capable of hybridizing with a nucleic acid of claim 39, or mRNA corresponding to the nucleic acid of claim 39.

80. A nucleic acid probe capable of hybridizing with a nucleic acid of claim 40, or mRNA corresponding to the nucleic acid of claim 40.

81. A nucleic acid probe capable of hybridizing with a nucleic acid of claim 47, or mRNA corresponding to the nucleic acid of claim 47.

82. An antibody or antibody fragment directed against a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID No. 9, 16, 22, 31, and 33.

83. An antibody or antibody fragment capable of preventing the interaction between the oncogenic forms of p53 and a polypeptide of claim 31.

84. A method for detecting a compound capable of specific binding to a polypeptide of claim 31, comprising:

contacting the compound or a sample containing the compound molecule with a polypeptide of claim 31 under conditions allowing interaction between the polypeptide and the compound, and

detecting specific binding to the polypeptide.

85. The method of claim 84, wherein the polypeptide comprises all or part of the amino acid sequence selected from the group consisting of SEQ ID NO. 9, 16, 22, 31, and 33.

86. A method for detecting a compound capable of modulating or inhibiting the interaction between the oncogenic forms of p53 and a polypeptide of claim 31, comprising:
adding the compound or a sample containing the compound to a composition comprising the oncogenic form of p53 or a fragment thereof, and the polypeptide under conditions that permit the specific binding of the polypeptide to the oncogenic form or fragment, and

detecting the inhibition of binding between the oncogenic form or fragment and the polypeptide or the displacement of bound polypeptide as compared to a control.

87. The method of claim 86, wherein the polypeptide comprises all or part of the amino acid sequence selected from the group consisting of SEQ ID NO. 9, 16, 22, 31, and 33.

88. A compound obtained from the method of claim 86.

89. A compound obtained from the method of claim 87.

90. A composition comprising a compound detected by the method of claim 84 and a pharmaceutically acceptable vehicle.

91. A composition comprising a compound of claim 88 and a pharmaceutically acceptable vehicle.

92. A composition comprising a compound of claim 89 and a pharmaceutically acceptable vehicle.

93. A method of using of a compound of claim 91, comprising administering the compound to a cell.

94. A method of using of a compound of claim 92, comprising administering the compound to a cell.

95. A method of using of a polypeptide capable of interacting with an oncogenic forms of p53, the polypeptide comprising all or part of an amino acid sequence selected from the group consisting of SEQ ID NO. 9, 33, 31, and 22, or a derivative thereof, comprising determining a structural component of the polypeptide responsible for binding to an oncogenic form of p53, and reproducing the component by a non-peptide compound or a peptide derivative.

96. A composition comprising an antisense oligonucleotide of claim 76 and a pharmaceutically acceptable vehicle.

97. A composition comprising an antibody or antibody fragment of claim 82 and a pharmaceutically acceptable vehicle.--

IN THE ABSTRACT

Please add the attached sheet containing the Abstract after the specification and claims.